PURPOSE: To determine whether adiponectin could reduce microalbuminuria and provide renal protective effects by improving endothelial dysfunction and uncoupling of the glomerular vascular endothelial growth factor (VEGF)-nitric oxide (NO) axis in streptozotocin-induced type 2 diabetic rats. METHODS: Wistar rats were randomly divided into normal control group, diabetic nephropathy (DN) group induced by high-fat feeding and streptozotocin, diabetic rats injected with adenovirus-expressed adiponectin (AD-AdipoQ), and diabetic rats injected with AD-IRES-EGFP as control. Blood and urine samples were collected. Endothelium-dependent vasodilatation (EDV) of the aorta was measured. Renal tissues were collected for CD34 immunohistochemistry. Glomerular NO and VEGF levels were measured by the Griess reaction and Western blot testing, respectively. RESULTS: Injections of AD-AdipoQ significantly increased serum adiponectin levels and reduced the urinary albumin-to-creatinine ratio in diabetic rats (P < 0.05). The levels of plasma glucose, serum insulin, high-sensitivity C-reactive protein, and malondialdehyde were significantly reduced in diabetic rats after injections of AD-AdipoQ (P < 0.05). Severe EDV impairment was observed in the DN group, which was improved by AD-AdipoQ. CD34 expression in the glomeruli was also higher in diabetic rats, indicating increased proliferation of glomerular endothelial cells. However, AD-AdipoQ improved the increased proliferation of endothelial cells in the glomeruli. Diabetic rats showed increased glomerular VEGF levels and reduced NO levels. This uncoupling of the VEGF-NO axis was partially improved by AD-AdipoQ. CONCLUSION: Adiponectin reduces the degree of microalbuminuria and has renal protective effects by improving endothelial dysfunction and uncoupling of the glomerular VEGF-NO axis in early diabetic nephropathy.
PURPOSE: To determine whether adiponectin could reduce microalbuminuria and provide renal protective effects by improving endothelial dysfunction and uncoupling of the glomerular vascular endothelial growth factor (VEGF)-nitric oxide (NO) axis in streptozotocin-induced type 2 diabeticrats. METHODS:Wistar rats were randomly divided into normal control group, diabetic nephropathy (DN) group induced by high-fat feeding and streptozotocin, diabeticrats injected with adenovirus-expressed adiponectin (AD-AdipoQ), and diabeticrats injected with AD-IRES-EGFP as control. Blood and urine samples were collected. Endothelium-dependent vasodilatation (EDV) of the aorta was measured. Renal tissues were collected for CD34 immunohistochemistry. Glomerular NO and VEGF levels were measured by the Griess reaction and Western blot testing, respectively. RESULTS: Injections of AD-AdipoQ significantly increased serum adiponectin levels and reduced the urinary albumin-to-creatinine ratio in diabeticrats (P < 0.05). The levels of plasma glucose, serum insulin, high-sensitivity C-reactive protein, and malondialdehyde were significantly reduced in diabeticrats after injections of AD-AdipoQ (P < 0.05). Severe EDV impairment was observed in the DN group, which was improved by AD-AdipoQ. CD34 expression in the glomeruli was also higher in diabeticrats, indicating increased proliferation of glomerular endothelial cells. However, AD-AdipoQ improved the increased proliferation of endothelial cells in the glomeruli. Diabeticrats showed increased glomerular VEGF levels and reduced NO levels. This uncoupling of the VEGF-NO axis was partially improved by AD-AdipoQ. CONCLUSION:Adiponectin reduces the degree of microalbuminuria and has renal protective effects by improving endothelial dysfunction and uncoupling of the glomerular VEGF-NO axis in early diabetic nephropathy.
Authors: Hui Jie Wang; Yuan Xiang Jin; Wan Shen; Jing Neng; Tao Wu; Yong Jie Li; Zheng Wei Fu Journal: Asia Pac J Clin Nutr Date: 2007 Impact factor: 1.662
Authors: Joachim Spranger; Anja Kroke; Matthias Möhlig; Manuela M Bergmann; Michael Ristow; Heiner Boeing; Andreas F H Pfeiffer Journal: Lancet Date: 2003-01-18 Impact factor: 79.321
Authors: Steven P Salvatore; Alluru S Reddi; Chandra B Chandran; James M Chevalier; Chike N Okechukwu; Surya V Seshan Journal: Nephrol Dial Transplant Date: 2013-09-29 Impact factor: 5.992
Authors: Maximilian von Eynatten; Dan Liu; Cornelia Hock; Dimitrios Oikonomou; Marcus Baumann; Bruno Allolio; Grigorios Korosoglou; Michael Morcos; Valentina Campean; Kerstin Amann; Jens Lutz; Uwe Heemann; Peter P Nawroth; Angelika Bierhaus; Per M Humpert Journal: Diabetes Date: 2009-06-09 Impact factor: 9.461
Authors: Hoon Suk Park; Ji Hee Lim; Min Young Kim; Yaeni Kim; You Ah Hong; Sun Ryoung Choi; Sungjin Chung; Hyung Wook Kim; Bum Soon Choi; Yong Soo Kim; Yoon Sik Chang; Cheol Whee Park Journal: J Transl Med Date: 2016-06-11 Impact factor: 5.531